Vimian Group AB (publ)
Vimian Group AB (publ) engages in the animal health business worldwide. It operates through Specialty Pharma, MedTech, Diagnostics, and Veterinary Services segments. The company offers proprietary diagnostics, prescription, and non-prescription treatments for preventive care and treatment of chronic conditions for companion animals under the Nextmune brand name; and molecular and immunodiagnostic… Read more
Vimian Group AB (publ) (VIMGF) - Net Assets
Latest net assets as of December 2025: $708.80 Million USD
Based on the latest financial reports, Vimian Group AB (publ) (VIMGF) has net assets worth $708.80 Million USD as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($1.11 Billion) and total liabilities ($401.00 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $708.80 Million |
| % of Total Assets | 63.87% |
| Annual Growth Rate | 66.96% |
| 5-Year Change | 97.64% |
| 10-Year Change | N/A |
| Growth Volatility | 142.9 |
Vimian Group AB (publ) - Net Assets Trend (2018–2025)
This chart illustrates how Vimian Group AB (publ)'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Vimian Group AB (publ) (2018–2025)
The table below shows the annual net assets of Vimian Group AB (publ) from 2018 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $708.80 Million | +0.33% |
| 2024-12-31 | $706.50 Million | +34.13% |
| 2023-12-31 | $526.71 Million | +9.39% |
| 2022-12-31 | $481.50 Million | +34.26% |
| 2021-12-31 | $358.64 Million | +30.77% |
| 2020-12-31 | $274.25 Million | +427.17% |
| 2019-12-31 | $52.02 Million | +165.57% |
| 2018-12-31 | $19.59 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Vimian Group AB (publ)'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 10900000000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $109.00 Million | 15.60% |
| Common Stock | $100.00K | 0.01% |
| Other Comprehensive Income | $-36.39 Million | -5.21% |
| Other Components | $626.19 Million | 89.60% |
| Total Equity | $698.90 Million | 100.00% |
Vimian Group AB (publ) Competitors by Market Cap
The table below lists competitors of Vimian Group AB (publ) ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
JEPA
F:JEPA
|
$829.15 Million |
|
Basic-Fit N.V
PINK:BSFFF
|
$829.31 Million |
|
Lecron Energy Saving Materials
SHE:300343
|
$829.53 Million |
|
Wisdom Marine Lines Co Ltd
TW:2637
|
$830.08 Million |
|
United Fire Group Inc
NASDAQ:UFCS
|
$828.99 Million |
|
Huhtamaki Oyj
NYSE:HMKIY
|
$828.92 Million |
|
Anhui Jiangnan Chemical Industry Co Ltd
SHE:002226
|
$828.66 Million |
|
Rent-A-Center Inc
F:RAC
|
$828.09 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Vimian Group AB (publ)'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 699,900,000 to 698,900,000, a change of -1,000,000 (-0.1%).
- Net income of 31,300,000 contributed positively to equity growth.
- New share issuances of 10,500,000 increased equity.
- Other comprehensive income decreased equity by 39,892,310.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $31.30 Million | +4.48% |
| Share Issuances | $10.50 Million | +1.5% |
| Other Comprehensive Income | $-39.89 Million | -5.71% |
| Other Changes | $-2.91 Million | -0.42% |
| Total Change | $- | -0.14% |
Book Value vs Market Value Analysis
This analysis compares Vimian Group AB (publ)'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.38x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 91.39x to 3.38x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-12-31 | $0.05 | $4.50 | x |
| 2019-12-31 | $0.11 | $4.50 | x |
| 2020-12-31 | $0.59 | $4.50 | x |
| 2021-12-31 | $1.02 | $4.50 | x |
| 2022-12-31 | $1.20 | $4.50 | x |
| 2023-12-31 | $1.16 | $4.50 | x |
| 2024-12-31 | $1.34 | $4.50 | x |
| 2025-12-31 | $1.33 | $4.50 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Vimian Group AB (publ) utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 4.48%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 7.36%
- • Asset Turnover: 0.38x
- • Equity Multiplier: 1.59x
- Recent ROE (4.48%) is above the historical average (3.22%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | -4.12% | -9.75% | 0.24x | 1.73x | $-2.71 Million |
| 2019 | -3.00% | -5.00% | 0.25x | 2.42x | $-5.32 Million |
| 2020 | 23.57% | 38.33% | 0.30x | 2.04x | $30.39 Million |
| 2021 | 1.84% | 3.80% | 0.27x | 1.79x | $-29.16 Million |
| 2022 | -1.49% | -2.56% | 0.30x | 1.92x | $-55.38 Million |
| 2023 | 1.87% | 2.97% | 0.34x | 1.85x | $-42.80 Million |
| 2024 | 2.64% | 4.94% | 0.34x | 1.59x | $-51.49 Million |
| 2025 | 4.48% | 7.36% | 0.38x | 1.59x | $-38.59 Million |
Industry Comparison
This section compares Vimian Group AB (publ)'s net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $914,015,556
- Average return on equity (ROE) among peers: -22.24%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Vimian Group AB (publ) (VIMGF) | $708.80 Million | -4.12% | 0.57x | $829.05 Million |
| Agilent Technologies Inc (A) | $4.08 Billion | 3.46% | 0.65x | $31.80 Billion |
| Amer Bio Medica (ABMC) | $3.38 Million | -26.64% | 1.08x | $3.55K |
| ADCNF (ADCNF) | $1.77 Billion | 2.65% | 1.64x | $172.01 Million |
| Advanced Biomed Inc. Common Stock (ADVB) | $3.48 Billion | 0.00% | 0.87x | $1.68 Million |
| ANGLE plc (ANPCF) | $18.44 Million | -77.14% | 0.38x | $34.42 Million |
| SeqLL Inc. (ATLN) | $8.18 Million | -45.26% | 0.31x | $35.63K |
| Avricore Health Inc (AVCRF) | $2.20 Million | -79.50% | 0.04x | $3.22 Million |
| Aspira Womens Health Inc (AWH) | $-11.46 Million | 0.00% | 0.00x | $664.47K |
| Biodesix Inc (BDSX) | $-198.03 Million | 0.00% | 0.00x | $50.38 Million |
| bioAffinity Technologies, Inc. (BIAF) | $-15.79 Million | 0.00% | 0.00x | $5.08 Million |